Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Condition:   Advanced Breast Cancer Interventions:   Drug: The combination of Dalpiciclib with physician-selected endocrine therapy;   Drug: Chemotherapy selected by the physician Sponsors:   Peking Union Medical College Hospital;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials